Anson Reports 6% Flyte Aviation Stake Held Without A Control Purpose

Private funds co-advised by Anson hold the shares, with voting and sale authority shared across the reporting persons.

Share
Anson Reports 6% Flyte Aviation Stake Held Without A Control Purpose

Anson Funds Management LP reported a 6% stake Monday in Flyte Aviation, which makes heart-rhythm medical devices and operates a private aviation charter business. The investment adviser’s SEC passive ownership disclosure covered September 30 and certified that the shares were held without a purpose of changing or influencing control.

The Funds Hold The Shares

Private funds co-advised by Anson Funds Management LP and Anson Advisors hold 1,261,874 common shares. The advisers can direct how those shares are voted and sold.

The ownership percentage uses 21,019,874 outstanding common shares, a figure Flyte reported in an SEC filing on October 2, 2026. Each reporting person listed shared voting authority over the funds’ position and zero sole voting authority.

Anson Management GP, the general partner of Anson Funds Management, can also direct votes and sales. Tony Moore, principal of both entities, has that authority, as do Amin Nathoo and Moez Kassam, directors of Anson Advisors. Those overlapping powers concern the same funds’ shares.

The holders certified that they bought and held the securities as part of ordinary business, without a control purpose. Anson is an active small-cap investor whose campaigns have included MEI Pharma and Match; its activity has involved frequent ownership filings, mostly concerning small-cap companies.

Heart Maps And Charter Flights

Flyte’s medical business serves hospitals with cardiac electrophysiology labs. Its VIVO system creates three-dimensional heart maps without an invasive procedure, helping physicians identify where irregular rhythms originate. LockeT temporarily holds sutures in place and helps close wounds.

The company sells medical devices directly in the United States and uses both direct sales and distributors internationally. Its annual report for the fiscal year ended December 31, 2025, said VIVO had been used in more than 1,000 procedures by more than 30 physicians across 11 countries.

Flyte also runs the FLYTE private aviation charter business. VJET shares fell about 6% to $0.46 in Monday trading; the company’s market value was $1 million as of Monday at 11:51 a.m. ET.

Sources